2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Evidence that Parkinson’s originates in the gut
A new study published in the journal ‘Neuron’ has found more evidence that Parkinson’s starts in the gut
The rationale for the TRANSEURO study
The TRANSEURO study is part-funded by Cure Parkinson’s and is investigating dopamine cell replacement therapy as a restorative treatment for people with Parkinson’s. It is being coordinated by Professor Roger Barker at the University of Cambridge, and it involves a European-wide network of Parkinson’s researchers….
The appendix and Parkinson’s
Although its exact role isn’t yet clear because findings have been conflicting, in this easy-to-read overview the link between the appendix in the gut and risk of developing Parkinson’s is discussed. This easy-to-read overview was published in the journal JAMA on the link between the…
GDNF trial results published
Results from a pioneering clinical trials programme that delivered an experimental treatment directly into the brain of people with Parkinson’s offer hope that it may be possible to restore damaged neurons. The findings from these ground-breaking trials are published today in Brain and the Journal of Parkinson’s Disease. …
GDNF – The phase 2 Bristol trial
In February 2019, the results of the ground-breaking phase 2 Bristol study investigating the use of a neurotrophic factor called GDNF (Glial cell-derived neurotrophic factor) in people with Parkinson’s were published.